Huiyu Capital

Hua Ning is the Managing Partner and Founder, making him the primary investment decision-maker. Public records show he previously held roles at Hongyun Huaning (Hangzhou) Biopharmaceutical Co., Ltd., suggesting life sciences expertise. The firm's analyst, Yu Haozhou, supports deal sourcing and diligence.

The firm focuses on balanced early-stage investments, with a particular emphasis on seed rounds. This positions Huiyu as a venture-stage capital provider rather than a growth or buyout fund.

Public co-investment records show positions in optics (Perfect Optics) and biotech (Zhengxi Biotech). The firm's strategy targets healthcare and biotech — sectors where its founder has operational experience.

Huiyu Capital typically co-invests alongside other firms. Documented co-investors include Kaifu Capital, Shenzhen Hi-tech Investment, Jiayi Fund, Oriental Biotech, and the government-linked Huzhou City Investment Group — indicating a collaborative deal model.

The source of capital backing Huiyu Capital has not been publicly disclosed. The firm does not appear in public filings as a registered fund, suggesting it may operate as a private vehicle for Hua Ning and possibly select co-investors.

Huiyu Capital is registered as an asset manager in Zhengzhou, China. Its legal structure — whether a single-family office, a multi-family office, or a standalone venture fund — is not publicly defined. The firm's co-investment pattern with government-linked entities suggests a flexible deal-by-deal approach.